We are focused, we are agile, we are driven, we do not cut corners, and we are guided by data and science. We are using this approach to develop and commercialize next generation anti-CD40 Ligand (CD40L) antibodies for patients in need of a potentially life-saving treatment. With AT-1501 as the cornerstone of our pipeline, Eledon is poised to leverage our expertise in both anti-CD40 Ligand biology and drug development to advan...
We are focused, we are agile, we are driven, we do not cut corners, and we are guided by data and science. We are using this approach to develop and commercialize next generation anti-CD40 Ligand (CD40L) antibodies for patients in need of a potentially life-saving treatment. With AT-1501 as the cornerstone of our pipeline, Eledon is poised to leverage our expertise in both anti-CD40 Ligand biology and drug development to advance therapies seeking to help patients undergoing organ or cellular transplantation, as well as those living with autoimmune or neurodegenerative diseases, all of whom face limited options.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.